From palliation to targeted therapy in myelofibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.Blood · 2011
   Trial
2. The Role of New Technologies in Myeloproliferative Neoplasms.Frontiers in oncology · 2019
   Review
3. Preclinical models for drug selection in myeloproliferative neoplasms.Current hematologic malignancy reports · 2013
   Review
4. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.Therapeutic advances in hematology · 2012
   Article
5. JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Therapeutic advances in hematology · 2011
   Article
6. Serum Interleukin-15 is a Marker of Alopecia Areata Severity.International journal of trichology
   Article

Corrections and comments

• Comment on
  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as